Targeting Cdc42 to improve cancer immunotherapy
Rational targeting of Cdc42 to benefit immunotherapy
['FUNDING_R01'] · CINCINNATI CHILDRENS HOSP MED CTR · NIH-10991373
This study is looking at how a special protein called Cdc42 can help make cancer treatments work better by boosting the body's immune cells, especially T cells, to fight tumors more effectively.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | CINCINNATI CHILDRENS HOSP MED CTR (nih funded) |
| Locations | 1 site (CINCINNATI, UNITED STATES) |
| Trial ID | NIH-10991373 on ClinicalTrials.gov |
What this research studies
This research investigates how targeting a specific protein, Cdc42, can enhance the effectiveness of immunotherapy for cancer patients. The approach focuses on understanding the role of T cells in fighting cancer and how cancer cells suppress these immune responses. By manipulating Treg cells, which normally inhibit T cell activity, the study aims to activate effector T cells to better combat tumors. The research utilizes a small molecule inhibitor to mimic genetic changes that destabilize Treg cells, potentially leading to improved anti-tumor immunity.
Who could benefit from this research
Good fit: Ideal candidates for this research are cancer patients who have not responded well to existing immunotherapies.
Not a fit: Patients with cancers that are not influenced by T cell activity may not receive benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer immunotherapies that benefit a larger number of patients.
How similar studies have performed: Other research has shown promise in targeting immune pathways to enhance cancer treatment, suggesting this approach could be effective.
Where this research is happening
CINCINNATI, UNITED STATES
- CINCINNATI CHILDRENS HOSP MED CTR — CINCINNATI, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: ZHENG, YI — CINCINNATI CHILDRENS HOSP MED CTR
- Study coordinator: ZHENG, YI
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: anti-cancer, anti-cancer immunotherapy, anti-cancer therapy, anticancer immunotherapy